The Potential for microRNA Therapeutics and Clinical Research
Tóm tắt
Từ khóa
Tài liệu tham khảo
Bartel, 2009, MicroRNAs: target recognition and regulatory functions, Cell, 136, 215, 10.1016/j.cell.2009.01.002
Bayraktar, 2018, miR-155 in cancer drug resistance and as target for miRNA-based therapeutics, Cancer Metastasis Rev., 37, 33, 10.1007/s10555-017-9724-7
Bayraktar, 2017, Cell-to-cell communication: microRNAs as hormones, Mol. Oncol., 11, 1673, 10.1002/1878-0261.12144
Biswas, 2018, MicroRNAs as therapeutic agents: the future of the battle against cancer, Curr. Top. Med. Chem., 18, 2544, 10.2174/1568026619666181120121830
Buschmann, 2018, Evaluation of serum extracellular vesicle isolation methods for profiling miRNAs by next-generation sequencing, J. Extracell. Vesicles, 7, 1481321, 10.1080/20013078.2018.1481321
Chen, 2015, In vivo delivery of miRNAs for cancer therapy: challenges and strategies, Adv. Drug Deliv. Rev., 81, 128, 10.1016/j.addr.2014.05.009
Choi, 2005, ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal, Cancer Cell Int., 5, 30, 10.1186/1475-2867-5-30
de Gooijer, 2018, Current chemotherapy strategies in malignant pleural mesothelioma, Transl. Lung Cancer Res., 7, 574, 10.21037/tlcr.2018.04.10
Elfimova, 2012, Circulating microRNAs: promising candidates serving as novel biomarkers of acute hepatitis, Front. Physiol., 3, 476, 10.3389/fphys.2012.00476
Gallo, 2012, The majority of microRNAs detectable in serum and saliva is concentrated in exosomes, PLoS One, 7, e30679, 10.1371/journal.pone.0030679
Garg, 2015, Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor, J. Drug Target., 23, 865, 10.3109/1061186X.2015.1029930
Ghosh, 2018, Combination therapy to checkmate Glioblastoma: clinical challenges and advances, Clin. Transl. Med., 7, 33, 10.1186/s40169-018-0211-8
Guo, 2018, The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells, EBioMedicine, 35, 204, 10.1016/j.ebiom.2018.08.001
Gupta, 2018, Extending arms of insulin resistance from diabetes to Alzheimer’s disease: identification of potential therapeutic targets, CNS Neurol. Disord. Drug Targets, 18, 172, 10.2174/1871527317666181114163515
Hopkins, 2008, Network pharmacology: the next paradigm in drug discovery, Nat. Chem. Biol., 4, 682, 10.1038/nchembio.118
Hu, 2018, Functional miRNAs in breast cancer drug resistance, Onco. Targets Ther., 11, 1529, 10.2147/OTT.S152462
Janssen, 2013, Treatment of HCV infection by targeting microRNA, N. Engl. J. Med., 368, 1685, 10.1056/NEJMoa1209026
Kanlikilicer, 2016, Ubiquitous release of Exosomal tumor suppressor miR-6126 from ovarian cancer cells, Cancer Res., 76, 7194, 10.1158/0008-5472.CAN-16-0714
Karagiannis, 2019, Induced pluripotent stem cells and their use in human models of disease and development, Physiol. Rev., 99, 79, 10.1152/physrev.00039.2017
Kawaguchi, 2016, Circulating MicroRNAs: a next-generation clinical biomarker for digestive system cancers, Int. J. Mol. Sci., 17, 10.3390/ijms17091459
Kim, 2015, Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome, Exp. Mol. Med., 47, e149, 10.1038/emm.2015.3
Kocerha, 2011, Altered microRNA expression in frontotemporal lobar degeneration with TDP-43 pathology caused by progranulin mutations, BMC Genomics, 12, 527, 10.1186/1471-2164-12-527
Kola, 2004, Can the pharmaceutical industry reduce attrition rates?, Nat. Rev. Drug Discov., 3, 711, 10.1038/nrd1470
Kristen, 2018, Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis, Neurodegener Dis. Manag., 9, 5, 10.2217/nmt-2018-0033
Lander, 2001, Initial sequencing and analysis of the human genome, Nature, 409, 860, 10.1038/35057062
Lanford, 2010, Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection, Science, 327, 198, 10.1126/science.1178178
Lekprasert, 2011, Assessing the utility of thermodynamic features for microRNA target prediction under relaxed seed and no conservation requirements, PLoS One, 6, e20622, 10.1371/journal.pone.0020622
Li, 2013, Alterations of serum levels of BDNF-related miRNAs in patients with depression, PLoS One, 8, e63648, 10.1371/journal.pone.0063648
McCall, 2017, Dual targeting of the cancer antioxidant network with 1,4-naphthoquinone fused gold(i) N-heterocyclic carbene complexes, Chem. Sci., 8, 5918, 10.1039/c7sc02153d
Mercatelli, 2008, The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice, PLoS One, 3, e4029, 10.1371/journal.pone.0004029
Montastier, 2018, Niacin induces miR-502-3p expression which impairs insulin sensitivity in human adipocytes, Int. J. Obes., 10.1038/s41366-018-0260-5
Ozcan, 2015, Preclinical and clinical development of siRNA-based therapeutics, Adv. Drug Deliv. Rev., 87, 108, 10.1016/j.addr.2015.01.007
Pammolli, 2011, The productivity crisis in pharmaceutical R&D, Nat. Rev. Drug Discov., 10, 428, 10.1038/nrd3405
Paskeviciute, 2019, Overcoming transporter-mediated multidrug resistance in cancer: failures and achievements of the last decades, Drug Deliv. Transl. Res., 9, 379, 10.1007/s13346-018-0584-7
Rashed, 2017, Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs, Oncotarget, 8, 20145, 10.18632/oncotarget.15525
Recchioni, 2013, Conventional and novel diagnostic biomarkers of acute myocardial infarction: a promising role for circulating microRNAs, Biomarkers, 18, 547, 10.3109/1354750X.2013.833294
Reid, 2016, Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer, Epigenomics, 8, 1079, 10.2217/epi-2016-0035
Riffo-Campos, 2016, Tools for sequence-based miRNA target prediction: what to choose?, Int. J. Mol. Sci., 17, 10.3390/ijms17121987
Scott, 2015, Thinking small: towards microRNA-based therapeutics for anxiety disorders, Expert Opin. Investig. Drugs, 24, 1, 10.1517/13543784.2014.997873
St Laurent, 2015, The landscape of long noncoding RNA classification, Trends Genet., 31, 239, 10.1016/j.tig.2015.03.007
Sun, 2014, Aberrant microRNA expression in peripheral plasma and mononuclear cells as specific blood-based biomarkers in schizophrenia patients, J. Clin. Neurosci., 22, 570, 10.1016/j.jocn.2014.08.018
Tsuji, 2019, Concise review: laying the groundwork for a first-in-human study of an induced pluripotent stem cell-based intervention for spinal cord injury, Stem Cells, 37, 6, 10.1002/stem.2926
Van Roosbroeck, 2017, Combining anti-Mir-155 with chemotherapy for the treatment of lung cancers, Clin. Cancer Res., 23, 2891, 10.1158/1078-0432.CCR-16-1025
van Zandwijk, 2017, Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study, Lancet Oncol., 18, 1386, 10.1016/S1470-2045(17)30621-6
Wagh, 2017, Levels of microRNA miR-16 and miR-155 are altered in serum of patients with tuberculosis and associate with responses to therapy, Tuberculosis, 102, 24, 10.1016/j.tube.2016.10.007
Wang, 2011, Circulating microRNAs are promising novel biomarkers of acute myocardial infarction, Intern. Med., 50, 1789, 10.2169/internalmedicine.50.5129
Wang, 2015, Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy, Sci. Rep., 5, 10201, 10.1038/srep10201
Washietl, 2012, Computational analysis of noncoding RNAs, Wiley Interdiscip. Rev. RNA, 3, 759, 10.1002/wrna.1134
Weber, 2010, The microRNA spectrum in 12 body fluids, Clin. Chem., 56, 1733, 10.1373/clinchem.2010.147405
Weir, 2011, Development of biomarkers for Huntington’s disease, Lancet Neurol., 10, 573, 10.1016/S1474-4422(11)70070-9
Xie, 2018, MicroRNA-298 reverses multidrug resistance to antiepileptic drugs by suppressing MDR1/P-gp expression in vitro, Front. Neurosci., 12, 602, 10.3389/fnins.2018.00602